Laurie Sehn

12:15
CAR-T vs bispecific antibodies for lymphoma
David Maloney et al.
11:43
Will knowledge of the molecular pathology of lymphoma improve clinical trials?
David Maloney et al.
7:45
Novel targets and agents for lymphoma
John Kuruvilla et al.
5:00
A breakthrough therapy: polatuzumab vedotin plus BR for R/R DLBCL
Laurie Sehn
iwNHL 2017: The future of lymphoma research and treatment
Catherine Bollard et al.
Novel lymphoma targets and agents
Andrew Zelenetz et al.
3:06
Results of trial on the use of interim PET scan to identify DLBCL
Laurie Sehn
1:34
The standard of care for DLBCL and double-hit lymphoma
Laurie Sehn
1:06
Recognizing the heterogeneity of DLBCL
Laurie Sehn
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals